This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: Targeted Anticancer Drugs and Immunosuppressants, Subject name: Pharmacology
[{'content': 'Which drug can be used in patient of CML with T315i mutation? \nSelect and explain. \nA. Imatinib, B. Nilotinib, C. Dasatinib, D. Ponatinib', 'role': 'user'}, {'content': 'Answer: D \nExplanation: Drugs against CML with T315I :* Omacetaxine* Ponatinib In CML there is BCR-ABL fusion , due to which there is hyperactivation of tyrosine kinase. ABL-BCR tyrosine kinase inhibitors:* First generation: Imatinib, * Second generation(active against Imatinib resistant cases): Dastanib, Nilotinib.* Third generation: Bosutinib, Ponatinib Ponatinib is the only TK inhibitor which is active against CML wth T315I mutation.', 'role': 'assistant'}]